# US 2021/0079040 A1 · Methods and compositions for treatment of cartilage and disc tissue pathologies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079040 A1
- Document ID: US20210079040A1
- Status: Published application
- Kind: A1
- Application number: 16/841,276
- Filed: 2020-04-06
- Published: 2021-03-18
- Earliest claimed: 2013-08-27
- Assignees: The Royal Institution for the Advancement of Learning/Mcgill University
- Applicants: The Royal Institution for the Advancement of Learning/Mcgill University
- Inventors: Fackson MWALE; John ANTONIOU; Lisbet HAGLUND; Peter J. ROUGHLEY; Rahul GAWRI; Laura M. EPURE; Michael P. GRANT
- Web page: https://patentgrep.com/patent/US20210079040A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An isolated polypeptide comprising a peptide selected from: i) DHX1SDNYT, wherein X1 is L or H (SEQ ID NO:3); ii) a conservative variant of i) iii) a fragment of i) or ii); wherein the conservative variant and/or fragment retains biological activity and the peptide is 15 or less amino acids as well as recombinant cells, and uses thereof.

## Claims

### Claim 1

An isolated polypeptide comprising a peptide selected from:
i)
(SEQ ID NO: 30)
DHX1X2X3X4X5X6;
X1 is any amino acid, optionally L, H, R, or Q;
X2 is S or L;
X3 is D, S or N;
X4 is N or D;
X5 is Y or S; and
X6 is T or Y;
ii) a conservative variant of i), and
iii) a fragment of i) or ii);
wherein the conservative variant or fragment retains biological activity and the peptide is 15 or fewer amino acids.

### Claim 2 (depends on 1)

The isolated polypeptide of claim 1, wherein the peptide consists of DHX1SDNYT (SEQ ID NO: 1), wherein X1 is L or H or a conservative variant thereof that retains biological activity.

### Claim 3 (depends on 1)

The isolated polypeptide of claim 1, comprising i) a peptide sequence consisting of DHLSDNYT (SEQ ID NO:2) or a conservative variant thereof that retains biological activity, or ii) a peptide sequence consisting of DHHSDNYT (SEQ ID NO:3) or a conservative variant thereof that retains biological activity.

### Claim 4 (depends on 1)

The isolated polypeptide of claim 1, wherein the peptide is 4, 5, 6, 7, 9, 10, 11, 12, 13, 14 or 15 amino acids.

### Claim 5 (depends on 1)

The isolated polypeptide of claim 1, comprising a peptide selected from:
i)
(SEQ ID NO: 6)
DHX1X2X3X4X5X6X7X8X9DX10X11X12X13
or
(SEQ ID NO: 4)
DHX1SDNYTX2DHDRX3I;
X1 is any amino acid, optionally L, H, R, or Q;
X2 is S or L;
X3 is D, S, or N;
X4 is N or D:
X5 is Y or S;
X6 is T or Y;
X7 is L, V, or T;
X8 is any amino acid, optionally D, G, N, or P;
X9 is H, Y, or P;
X10 is R or Q;
X11 is A, V, or D;
X12 is I or R; and
X13 is H or V;
ii) a conservative variant of i); and
iii) a fragment of i) or ii)
wherein the conservative variant or fragment retains biological activity.

### Claim 6 (depends on 5)

The isolated polypeptide of claim 5, wherein the sequence is:
i) DHLSDNYTLDHDRAI (SEQ ID NO: 9) or a conservative variant or fragment thereof that retains biological activity or has at least 80% sequence identity to SEQ ID NO: 9, or
ii) DHHSDNYTVDHDRVI (SEQ ID NO: 10) or a conservative variant or fragment thereof that retains biological activity or has at least 80% sequence identity to SEQ ID NO: 10.

### Claim 7 (depends on 1)

The isolated polypeptide of claim 1, wherein the peptide is conjugated to a stabilizing moiety or carrier.

### Claim 8 (depends on 1)

An isolated nucleic acid that encodes the polypeptide of claim 1.

### Claim 9 (depends on 8)

A vector comprising the isolated nucleic acid of claim 8.

### Claim 10 (depends on 1)

A recombinant cell expressing the polypeptide of claim 1.

### Claim 11 (depends on 10)

The recombinant cell of claim 10, wherein the cell is a chondrocyte lineage cell, a stem cell, or a disc cell.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the isolated polypeptide of claim 1 and a pharmaceutically acceptable carrier, stabilizing agent, or diluent.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a scaffold formed of a biocompatible material comprising the isolated polypeptide of claim 1 and a pharmaceutically acceptable carrier, stabilizing agent, or diluent.

### Claim 14 (depends on 1)

A method of producing an induced cartilage, chondrocyte cell, or disc cell with increased matrix synthesis, the method comprising culturing the cartilage, chondrocyte cell, or disc cell with an effective amount of the isolated polypeptide of claim 1 under conditions to induce proteoglycan or collagen synthesis, thereby producing an induced cartilage, chondrocyte cell, or disc cell with increased matrix synthesis.

### Claim 15 (depends on 1)

A method of producing an induced cartilage, chondrocyte cell, or disc cell with increased matrix synthesis for implanting into a subject, the method comprising culturing the cartilage, chondrocyte cell, or disc cell with an effective amount of the isolated polypeptide of claim 1 under conditions to induce proteoglycan and collagen synthesis, thereby producing an induced cartilage, chondrocyte cell, or disc cell with increased matrix synthesis.

### Claim 16 (depends on 1)

A method of alleviating a symptom of and/or treating a cartilage or disc disorder, comprising administering to a subject in need thereof the isolated polypeptide of claim 1.

### Claim 17 (depends on 10)

A method of alleviating a symptom of and/or treating a cartilage or disc disorder, comprising administering to a subject in need thereof the recombinant cell of claim 10.

### Claim 18 (depends on 12)

A method of alleviating a symptom of and/or treating a cartilage or disc disorder, comprising administering to a subject in need thereof the pharmaceutical composition of claim 12.

### Claim 19

A liposome comprising an isolated polypeptide having the sequence DHX1X2X3X4X5X6 (SEQ ID NO: 30); wherein X1 is L, H, R, or Q; X2 is 5; X3 is D, S or N; X4 is N; X5 is Y; and X6 is T.

### Claim 20

An induced cartilage, chondrocyte cell, or disc cell with increased matrix synthesis for implanting into a subject, wherein the cartilage, chondrocyte, or disc cell is made by a method comprising culturing a cartilage, chondrocyte, or disc cell with an effective amount of an isolated polypeptide comprising a peptide selected from:
i)
(SEQ ID NO: 30)
DHX1X2X3X4X5X6;
X1 is any amino acid, optionally L, H, R, or Q;
X2 is S or L;
X3 is D, S or N;
X4 is N or D;
X5 is Y or S; and
X6 is T or Y;
ii) a conservative variant of i), and
iii) a fragment of i) or ii);
wherein the conservative variant or fragment retains biological activity and the peptide is 15 or fewer amino acids,
thereby producing an induced cartilage, chondrocyte cell, or disc cell with increased matrix synthesis.
